leadf
logo-loader
viewSareum Holdings PLC

Sareum's Tim Mitchell upbeat after 'very successful' early-stage cancer trial

Sareum Holdings PLC (LON:SAR) chief executive Tim Mitchell caught up with Proactive London's Andrew Scott to discuss some preliminary efficacy data released on a drug that Sareum helped to develop.

Of particular note was the impact SRA737 had in combination with a common chemotherapy called gemcitabine in patients with anogenital cancer ... ''the trial's been very, very successful indeed'', Mitchell says.

The data's been taken from a phase I/II clinical trial undertaken by Sierra Oncology, which licensed the drug candidate in a deal worth up to US$328.5mln plus royalties.

Quick facts: Sareum Holdings PLC

Price: 2.225 GBX

AIM:SAR
Market: AIM
Market Cap: £72.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

on 12/8/20

2 min read